Please reload


Please reload

Lit Review Feb #4

February 28, 2018

Disclaimer: this compilation of synopses have been collected from multiple sources, including Mark Crislip's Puscast, Journal Watch Infectious Diseases, Medscape Infectious Diseases, CDC MMWR, AMA Morning Rounds, ProMED Mail, Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and more. I chose these articles based on their relevance to clinical microbiology and would be of interest to my fellows, and some other pieces that I found amusing to read. All credit goes to these original contributors. I'm just a messenger :).

Drugs that reduce transmission of falciparum malaria

  • Current artemisinin-containing regimens and alternative  sulfadoxine-pyrimethamine /amodiaquine combination reduce gametocyte development, but do not have effect on existing mature PF gametocytes that are ready to infect mosquitoes at time of initiation of treatment

  • Primaquine and methylene blue have potent PF gametocidal effects, administered orally

    • High dose of primaquine can induce hemolysis I G6PD patients, but single low dose is ok

    • MB is pretty safe, administer in a 3-day course

    • Use of either, combined with standard regimens reduced transmission completely at day 2

    • The only side effect is with MB (blue pee)

New HBV vaccine Recommended by Advisory Committee on Immunization Practices

  • Heplisav-B: the first new hepatitis B vaccine in 25 years.

  • Given in two shots over a month, as opposed to regimen of three doses over six months

Notes from the Field: Increase in Acute Hepatitis B Infections — Pasco County, Florida, 2011–2016

  • From 2011 to 2016: number of acute HBV-infected persons in Pasco County increased from 1.5 to 17.28 per 100,000 residents (p<0.001)

  • More than half reported injection drug use in the 6 months preceding symptom onset

  • HIV?

WHO Announces Recommended Components of 2018–19 Flu Vaccine

  • For 2018–19 season in the northern hemisphere

    • An A/Michigan/45/2015 (H1N1)pdm09-like virus

    • An A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus

      • Switched from an A/Hong Kong/4801/2014 (H3N2)-like virus due to lack of efficacy

    • A B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage)

      • Switched from a B/Brisbane/60/2008-like (B/Victoria lineage) due to genetic changes in circulating viruses

    • A B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage)

      • Omitted in trivalent vaccines

Neonatal Immunization with a Novel Vaccine Against Rotavirus

  • Novel RV3-BB vaccine: strain RV3 (isolated from asymptomatic infants, natural infection with this virus is associated with prevention of GE for 3 years)

  • Study in >1500 infants in Indonesia

    • Four doses the followed for 18 months

    • Vaccine efficacy: 75% (neonatal schedule - 0 to 5 days, 8 weeks, and 14 weeks of age), 51% (infant schedule - 8 weeks, 14 weeks, and 18 weeks of age), and 63% (overall)

    • Time to first gastroenteritis significantly longer among vaccine recipients compared with placebo

    • No intussusception occurred during standard 21-day risk period

  • Rotavirus vaccination in neonates thought to be meh due to possibility of low vaccine strain binding in immature gut and immature immune system, but this proved otherwise

Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study

  • Case-control study in 349 women in sub-Saharan Africa with or without HIV

  • Vaginal samples collected and follow-up for HIV acquisition

    • 16S metagenomics, bacteria-specific PCR

    • 55 acquired HIV, compared with 55 control cases

  • Lower relative abundance of Lactobacillus iners associated with higher probability of HIV acquisition

  • Higher relative abundance of these organisms associated with higher probability of HIV acquisition

    • Parvimonas species type 1 and type 2

    • Gemella asaccharolytica

    • Mycoplasma hominis

    • Leptotrichia/Sneathia

    • Eggerthella species type 1

    • Megasphaera

  • Nugent score of 7-10 associated with twice risk of HIV acquisition compared to lower scores

  • Probiotics to prevent transmission?

Strains of bacterial species induce a greatly varied acute adaptive immune response: The contribution of the accessory genome

  • Why do clinical courses of infection vary between individuals?

    • Differences in bacteria vs host immune responses?

  • Study of acute adaptive T- and B-cell immune responses induced ex vivo by various Staphylococcus aureus (16) and Streptococcus pyogenes (3) strains using lymphocytes isolated from 11 healthy individuals

    • Evaluated acute adaptive immune responses (T- and B-cell mediated)

    • A lot of variability in strength of immune responses between strains, but strength of responses of same strain among individuals was pretty similar

      • The bacteria itself may have more effect on immune response (rather than host)

    • Knocking out accessory genomes (leaving “core” genome): blunted immune responses

      • Maybe it’s the accessory genome that matters

        • May contain unique combination of virulence determinants and superantigens

Culture-Negative Septic Shock Compared With Culture-Positive Septic Shock: A Retrospective Cohort Study

  • Studied clinical characteristics and outcomes of culture-negative septic shock (2651) in comparison with culture-positive septic shock (6019)

  • Survival and severity of disease (per Acute Physiology and Chronic Health Evaluation II - APACHE II scores) similar among groups


  • Delay in antimicrobial treatment negatively affected mortality in both groups

  • Moral of the story: the most important thing is to recognize clinical sepsis and initiate early appropriate antimicrobial therapy regardless of culture results

Topical Antibiotic Use Coselects for the Carriage of Mobile Genetic Elements Conferring Resistance to Unrelated Antimicrobials in Staphylococcus aureus

  • New Zealand: unrestricted use of mupirocin and fusidic acid (in the 90s) associated with increase in isolates with high levels of resistance (to 28%) in 2015 – among the highest in the world

  • ST5 MRSA, ST1 MRSA, ST1 MSSA seemed to predominate

  • This study looked at ST1 isolates

    • WGS

      • fusC on chromosome and mupA on plasmid, but both in mobile genetic element cassettes

      • BEAST timed phylogeny: expansion of strains harboring mupA occurred same time as initiation of clinical use of mupirocin in the early 90s, also co-selects for isolates harboring fusc, which experienced another expansion shortly after fusidic acid became available in the late 90s-early 2000s

Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection

  • Human monoclonal antibody directed against the toxin B (Bezlotoxumab) implicated in prevention of CDI recurrence in patients receiving antibiotic therapy for CDI

  • Cost-effectiveness study using data from 2 RCTs (comparing outcomes between SOC and giving Mab along with antibiotics to treat CDI) and computer models

    • Use of mab

      • Reduced first recurrence by 10.1%, total recurrences by 16.7%, and 180-day mortality by 1.1%

      • 0.12 quali